JPH10218784A - Medicine for external use for treating allergic dermatitis - Google Patents

Medicine for external use for treating allergic dermatitis

Info

Publication number
JPH10218784A
JPH10218784A JP2274397A JP2274397A JPH10218784A JP H10218784 A JPH10218784 A JP H10218784A JP 2274397 A JP2274397 A JP 2274397A JP 2274397 A JP2274397 A JP 2274397A JP H10218784 A JPH10218784 A JP H10218784A
Authority
JP
Grant status
Application
Patent type
Prior art keywords
allergic dermatitis
medicine
tea
extract
tea leaf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2274397A
Other languages
Japanese (ja)
Inventor
Hiroko Ikeuchi
Susumu Kiyokawa
Hideo Namiki
木 秀 男 並
内 裕 子 池
川 晋 清
Original Assignee
Frontier:Kk
Susumu Kiyokawa
株式会社フロンティア
清川 晋
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Abstract

PROBLEM TO BE SOLVED: To prepare a medicine for external use effective in treating allergic dermatitis, especially atopic dermatitis.
SOLUTION: This medicine for external use for treating allergic dermatitis is obtained by using an extract from a green tea leaf as an active ingredient. In the medicine for external use for treating allergic dermatitis, the dried green tea leaf itself or the green tea extract contained in the form of a green tea extract solution and its dried substance may have any conventional well-known dosage form suitable for direct application to dermal inflammatory sites and may be an ointment, a coating solution, an emulsion and a cream or a bathing agent.
COPYRIGHT: (C)1998,JPO

Description

【発明の詳細な説明】 DETAILED DESCRIPTION OF THE INVENTION

【0001】 [0001]

【発明の技術分野】本発明は、アレルギー性皮膚炎、特にアトピー性皮膚炎の治療に有効な、茶葉抽出物を有効成分として用いたアレルギー性皮膚炎治療用の外用薬に関する。 FIELD OF THE INVENTION The present invention relates include allergic dermatitis, particularly effective in the treatment of atopic dermatitis, relates ointment for allergic dermatitis treatment with the tea leaf extract as an active ingredient.

【0002】 [0002]

【発明の技術的背景】ヒトの皮膚には多くの疾患が生じ、これら疾患の中には急性または慢性疾患、先天的または後天的疾患、伝染性または非伝染性疾患など、さまざまなものが含まれている。 The human skin BACKGROUND OF THE INVENTION cause many diseases, acute or chronic diseases in these diseases, congenital or acquired diseases, such as infectious or non-infectious disease, include those various It has been.

【0003】このような皮膚疾患の内、動物、植物または化学物質等の抗原と接触することにより感作されて起こるアレルギー性皮膚炎は、それにかかり易い素因が遺伝する傾向があり、かつ痒みの強い慢性的症状を示すことが多い。 [0003] Among such skin diseases, animal, allergic dermatitis which occurs is sensitized by contacting with antigen, such as plant or chemicals tend to easily predisposition to genetic consuming it, and itching Mino often show a strong chronic symptoms.

【0004】例えば、アトピー性皮膚炎は、毛、羽毛、 [0004] For example, atopic dermatitis, hair, feathers,
ダニ、細菌および真菌などの天然物、或いは化学繊維などの人工物などさまざまな物質を抗原として発症する。 Mites, natural products, such as bacteria and fungi, or various materials such as artificial materials such as chemical fibers develop as an antigen.
またアトピー性皮膚炎は、特に乾燥肌の神経質な人および幼児に多く、患者およびその家族が、蕁麻疹、花粉アレルギーおよび気管支喘息などのアレルギー性疾患の病歴を有している場合が多い。 The atopic dermatitis, particularly many nervous people and infants dry skin, patients and their families, urticaria, often has a history of allergic diseases such as pollen allergies, and bronchial asthma. そして、この皮膚炎は、増悪・寛解を繰り返す、極めて痒みの強い湿疹を主病変とする慢性疾患である。 Then, this dermatitis, repeated exacerbations, remission, is a chronic disease in which the extremely itchy strong eczema and the main lesion.

【0005】このようなアトピー性皮膚炎は、長期間継続する痒みによる精神的および肉体的な消耗が激しいため、有効な治療方法の確立が強く望まれているものの、 [0005] Such atopic dermatitis, since severe mental and physical exhaustion due itching long lasting, although the establishment of an effective therapeutic method is strongly desired,
抗原物質が多様である他、単なる物理的刺激でも発症し、また食物が皮膚症状に関与する場合もあるなど発症メカニズムが複雑で治療が困難である。 Other antigenic substance is diverse, developed at mere physical stimuli, also developed mechanisms such cases also the food involved in skin condition is difficult to complicated treatment.

【0006】近年、アトピー性皮膚炎の最も有効な治療薬として、ステロイド外用薬が用いられている。 In recent years, as the most effective treatment for atopic dermatitis, topical steroid are used. しかしながら、ステロイド外用薬は、その薬効の強弱や、塗布部位及び時期などを厳密に選択する必要があり、これを間違うと症状が殆ど改善されず、返って悪化することもあった。 However, topical steroid, the strength and efficacy, strict must select such application site and timing, it is hardly improved symptoms when wrong this was sometimes deteriorate returned. 例えば、ステロイド外用薬を長期間連続使用した場合には、ステロイド潮紅、酒さ様皮膚炎などの副作用が起こる可能性がある。 For example, in the case of a long period of continuous use of the topical steroid is, there is a possibility that the steroid flushing, side effects such as rosacea-like dermatitis occur. また、有効がないという理由でステロイド外用薬の患部への塗布を中止すると、リバウンドにより症状が著しく悪化することとなる。 In addition, If you stop the application to the affected area of ​​topical steroid on the grounds that effective is not, so that the symptoms are significantly exacerbated by the rebound.

【0007】したがって、ステロイド外用薬の使用範囲および使用量を可能な限り低減することができ、かつステロイド外用薬を用いた従来の治療ではその症状に改善が見られなかった場合でも有効なアレルギー性皮膚炎治療用、特にアトピー性皮膚炎治療用の外用薬の開発が強く望まれていた。 Accordingly, it is possible to reduce as much as possible the use range and amount of topical steroid, and effective allergenic even if the improvement in the symptoms was not seen in conventional therapy with topical steroid for dermatitis, particularly the development of topical agents for the treatment of atopic dermatitis has been strongly desired.

【0008】 [0008]

【発明の目的】本発明は、このような従来技術にともなう問題点を解決するためになされたものであって、アレルギー性皮膚炎、とくにアトピー性皮膚炎の治療に有効な外用薬を提供することを目的としている。 SUMMARY OF THE INVENTION The present invention was made to solve the problems associated with the prior art, allergic dermatitis, in particular to provide an effective topical agent for the treatment of atopic dermatitis It is aimed at.

【0009】 [0009]

【発明の概要】本発明に係るアレルギー性皮膚炎治療用外用薬は、茶葉抽出物を有効成分として用いることを特徴としている。 Allergic dermatitis therapeutic medicine for external application according to the present invention SUMMARY OF THE INVENTION are characterized by using a tea leaf extract as an active ingredient. 前記茶葉抽出物は、乾燥茶葉そのもの、 The tea leaf extract, dried tea leaves themselves,
茶葉抽出液および茶葉抽出液乾燥体から選択される何れの形態で含まれていてもよく、かつ下葉を原料として用いることが特に好ましい。 May be contained in any form selected from extract of tea leaves and extract of tea leaves dry matter, and it is particularly preferable to use the lower leaf as a starting material.

【0010】また、本発明に係るアレルギー性皮膚炎治療用外用薬は、前記茶葉抽出物に加えて、ビタミンCおよびビタミンEの少なくとも何れか一方を含むことが好ましい。 Moreover, allergic dermatitis therapeutic medicine for external application according to the present invention, in addition to the tea leaf extract preferably contains at least one of vitamin C and vitamin E.

【0011】このような本発明に係るアレルギー性皮膚炎治療用外用薬は、種々のアレルギー性皮膚炎への適用が期待でき、特にアトピー性皮膚炎の治療に有効である。 [0011] allergic dermatitis therapeutic medicine for external application according to the present invention is applicable to a variety of allergic dermatitis can be expected, it is particularly effective in the treatment of atopic dermatitis. 本発明のアレルギー性皮膚炎治療用外用薬は、様々な剤型で適用可能であり、例えば軟膏、溶液、エマルジョンおよびクリーム等のいずれの形態であってもよく、 Allergic dermatitis therapeutic medicine for external application of the present invention is applicable in a variety of dosage forms, such as ointments, solutions, may be in any form, such as emulsions and creams,
特に、入浴時に浴槽に添加する入浴剤として用いることが治療上有効である。 In particular, it is used as a bath agent to be added to the tub when bathing is therapeutically effective.

【0012】 [0012]

【発明の具体的説明】以下、本発明に係るアレルギー性皮膚炎治療用外用薬を、さらに具体的に説明する。 DETAILED DESCRIPTION OF THE INVENTION Hereinafter, an allergic dermatitis therapeutic medicine for external application according to the present invention will be described more specifically.

【0013】本発明に係るアレルギー性皮膚炎治療用外用薬は、茶葉抽出物を有効成分として用いている。 [0013] allergic dermatitis therapeutic medicine for external application according to the present invention uses a tea leaf extract as an active ingredient. 本発明で適用される茶葉抽出物の主成分は、カフェイン類、 The main component of the tea leaf extract applied in the present invention, caffeine,
茶ポリフェノール類(カテキン類、タンニン類、テアフラビン類)およびフラボノイド類であり、その他、タンパク質、アミノ酸類、糖類および植物色素、ビタミン類等の様々な有機成分を含む。 Tea polyphenols (catechins, tannins, theaflavins) a and flavonoids, and other, including proteins, amino acids, sugars and vegetable dyes, various organic components such as vitamins. また、茶葉抽出物は、カリウム、アルミニウム、弗素などの無機成分を含んでいる。 Also, the tea leaf extract contains potassium, aluminum, inorganic components such as fluorine.

【0014】茶葉抽出物を外用薬として用いた場合、その何れの成分が、アレルギー性皮膚炎、特にアトピー性皮膚炎のどの発症経路に作用するかは明らかではない。 [0014] When using the tea leaf extract as an external agent, any of its components, allergic dermatitis, are not clear or particularly act on which the development path of atopic dermatitis.
例えば、茶葉抽出物に含まれる茶フェノール類、例えばエピガロカテキンガレート等のエピガロカテキン類あるいは天然カフェインが、経口投与する抗アレルギー剤として有効であることが知られている。 For example, tea phenols contained in the tea leaf extract, for example, epigallocatechin compounds or natural caffeine like epigallocatechin gallate, are known to be effective as an antiallergic agent is administered orally. エピガロカテキンガレートが、ヒスタミン遊離活性に対して強い抑制活性を示し、あるいは皮膚から分泌される脂質に含まれる脂肪酸の過酸化物化反応を抑制することが知られている。 Epigallocatechin gallate showed strong inhibitory activity on histamine-releasing activity, or to suppress the peroxide reaction of fatty acids contained in the lipids secreted from the skin are known.
また、茶葉抽出物を、特定の油脂(α-リノレイン酸、 Further, the tea leaf extract, certain fats (alpha-linolenic acid,
エイコサペンタエン酸、ドコサヘキサエン酸等)と混合し、経口または注射等の非経口で投与すると、特定油脂のアレルギー抑制効果を強化することが報告されている。 Eicosapentaenoic acid were mixed with docosahexaenoic acid), when administered parenterally oral or injectable, etc., it has been reported to enhance the allergic effect of suppressing a particular oil. さらに、茶葉抽出物に含まれる特定のタンニンあるいはサポニン化合物が、抗アレルギーまたは抗炎症作用を示すとの報告もある。 Furthermore, the particular tannin or saponin compounds contained in the tea leaves extract, it is also reported to exhibit anti-allergic or anti-inflammatory effect.

【0015】しかしながら、茶葉抽出物を直接アレルギー性皮膚炎の炎症部分に適用すること、およびその場合の効果あるいは炎症発症経路への作用に関しては、全く知られていなかった。 [0015] However, applying the inflammation part of the tea leaf extract directly allergic dermatitis and for the action of the to effect or inflammation onset path when, has not been known at all. 特に、本発明のように、茶葉抽出物を外用薬の有効成分として用い、入浴時に入浴剤として浴槽に添加してアレルギー性皮膚炎、特にアトピー性皮膚炎の治療に適用すること、およびその治療効果に関しては何ら報告されていない。 In particular, as in the present invention, applying the tea leaf extract used as an active ingredient of the external medicine was added to bath in allergic dermatitis as bathing agent during bathing, especially the treatment of atopic dermatitis and its treatment there has been no report with respect to the effect.

【0016】また、最近では、アトピー性皮膚炎の発症素因として、これまで知られていたアレルギーによる炎症の発生という病態とは別に、ドライスキンによる皮膚のバリヤー障害も大きく係わっていると考えられている。 [0016] Recently, as a predisposition for atopic dermatitis, which is a condition that inflammation caused by allergy was known to separate, believed to be involved greater barrier disorders of the skin due to dry skin there. 即ち、乾燥した肌では、皮膚表面の角質細胞間をつなぎとめるセラミドという脂質が不足しており、この脂質の不足によって角質細胞間に隙間ができる。 That is, in the dry skin, and insufficient lipid that tether ceramide between corneocytes on the skin surface, a gap is formed between the corneocytes by the lack of this lipid. この隙間から水分が逃げると角質細胞は干からびて剥がれ易くなり、かつこの隙間をぬって抗原などの外部からの物質が表皮内に侵入し易くなるため、アトピー性皮膚炎の患者では、汗や、摩擦等の軽度の物理的刺激でも皮膚炎が簡単に発症することとなる。 The moisture escapes from the gap corneocytes easily peel off dried up, and since the material from outside such as an antigen painted this gap tends to penetrate into the epidermis, in patients with atopic dermatitis, or sweat, so that the dermatitis may develop easily even mild physical stimulation such as friction.

【0017】本発明に係るアレルギー性皮膚炎治療用外用薬は、有効成分である茶葉抽出物をアレルギー性皮膚炎の炎症部分に直接塗布することで、茶葉抽出物によるアレルギー抑制作用を発揮されるとともに、その保湿作用などで上述の皮膚バリヤー機能を回復あるいは向上させることで、特に優れた消炎効果を示すものと考えられる。 [0017] allergic dermatitis therapeutic medicine for external application according to the present invention, a tea leaf extract as an active ingredient by applying directly to the inflamed portions of allergic dermatitis is exerted allergic inhibiting effect of the tea leaf extract together, by restoring or improving the above-mentioned skin barrier function like its moisturizing effect, it would indicate particularly excellent antiphlogistic effect.

【0018】また、本発明で適用される茶葉抽出物は、 Further, the tea leaf extract applied in the present invention,
通常飲料用に用いられる新芽ではなく、新芽以外の茶葉、所謂下葉または古葉と呼ばれる茶葉の抽出物であることが好ましい。 Rather than shoots usually used for beverages, tea other than sprouts is preferably an extract of tea leaves which is a so-called lower lobe or old leaves. 茶葉に含まれるカテキン類の総量は、 The total amount of catechins contained in the tea leaves,
新芽よりも古葉に多く、特にエピガロカテキンガレートの含有量が増加する。 Than shoots much to old leaves, in particular the content of epigallocatechin gallate is increased.

【0019】本発明では、茶葉抽出物は、患部炎症部分に直接有効成分として作用できればどのような形態で外用薬に含まれていてもよい。 In the present invention, the tea leaf extract may be included in the topical drug in any form as long acting as a direct active ingredient to the affected area of ​​inflammation. したがって、本発明の外用薬は、その剤型・処方に合わせて、茶葉抽出物を、例えば乾燥茶葉そのもの、茶葉抽出液およびその乾燥体などの種々の形態で含むことができる。 Therefore, external medicine of the present invention depending on their dosage form, the formulation, the tea leaf extract, such as dry tea leaves themselves, extract of tea leaves and can be included in various forms, such as the dried body. この内、乾燥茶葉および茶葉抽出液乾燥体は、粉体であってもよい。 Of these, dried tea leaves and extract of tea leaves dried body may be a powder.

【0020】茶葉抽出液は、茶葉あるいは乾燥茶葉を用い、従来公知の何れの方法で抽出してもよい。 The tea leaves extract using tea leaves or dried tea leaves, it may be extracted by a conventionally known any method. 例えば、 For example,
茶葉抽出液は、茶葉あるいは乾燥茶葉を水、熱湯、メタノール水溶液、エタノール水溶液およびアセトン水溶液等から選択される抽出溶媒で抽出して得ることができる。 Extract of tea leaves may be the tea leaves or dried tea leaves water, hot water, may be extracted by the extraction solvent methanol solution is selected from aqueous ethanol and aqueous acetone and the like. この内、得られた粗製抽出液が皮膚に刺激性がある有機溶媒を含まないため有機溶媒の除去操作を必要とせずそのまま使用でき、かつ抽出操作も簡便であることから、熱湯での抽出が好ましい。 Among them, since the crude extract obtained is removal operation of the organic solvent contains no organic solvent is irritating to the skin can be directly used without the need for, and extraction operation is simple, the extraction with hot water preferable. また、茶葉抽出液の粉体は、このような茶葉抽出液から、抽出溶媒を留去して調製することができる。 Further, the powder of the extract of tea leaves from such tea leaves extract, extraction solvent can be prepared by removing the.

【0021】本発明のアレルギー性皮膚炎治療用外用薬は、このような茶葉抽出物に加えて、ビタミンC(アルコルビン酸またはアスコルビン酸塩)およびビタミンE [0021] allergic dermatitis therapeutic medicine for external application of the present invention, in addition to such tea leaf extract, vitamin C (ascorbic acid or ascorbate) and vitamin E
(酢酸d-αトコフェロール)の少なくとも何れか一方を助剤として含むことが好ましい。 Preferably contains at least one of (acetic d-alpha tocopherol) as an aid. ビタミンCおよび/またはビタミンEを含むことにより、ビタミンEの抗酸化作用によって過酸化脂質の増加を防止し、かつビタミンCによってエネルギー代謝の活性化をうながす効果を期待することができる。 The inclusion of vitamin C and / or vitamin E, to prevent an increase in lipid peroxidation by antioxidant effect of vitamin E, and it is possible to expect an effect of prompting the activation of energy metabolism by vitamin C. また、ビタミンCを入浴剤に加えた場合、水道水に添加されている塩素を分解し、皮膚への刺激を軽減させることもできる。 Also, when adding vitamin C to the bath agent to decompose the chlorine that is added to the tap water, it is also possible to reduce the skin irritation.

【0022】助剤としてのビタミンCおよびビタミンE [0022] vitamin C and vitamin E as an aid
の添加量は、外用薬の剤型、患者の症状などに合わせて、適宜選択することができる。 The amount of addition, ointment dosage form, fit like symptoms of the patient, it can be appropriately selected. 本発明の外用薬は、乾燥茶葉そのもの、茶葉抽出液およびその乾燥体の形態で含まれる茶葉抽出物を、皮膚炎症部分に直接接触・作用させるのに適した従来公知の如何なる剤型を有していてもよい。 External medicine of the present invention, dried tea leaves themselves, the tea leaf extract contained in the form of a tea leaf extract and its dry body have any conventionally known dosage forms which are suitable for direct contact and acts on the skin of inflammation it may be.

【0023】即ち、例えば、本発明のアレルギー性皮膚炎治療用外用薬は、茶葉抽出液、所望により粉体とした乾燥茶葉および茶葉抽出物乾燥体そのものであってもよく、更には、場合により添加剤(アルコルビン酸等)、 [0023] That is, for example, allergic dermatitis therapeutic medicine for external application of the present invention, the tea leaf extract may be a dried tea leaves and tea leaf extract dried body itself was desired powder, furthermore, optionally additives (such as ascorbic acid),
および生理学上および製剤上許容される1種または2種以上の担体、賦形剤または製剤用助剤を加えて、様々な剤型とすることができる。 And physiologically and one or more carriers formulation on acceptable, the addition of excipients or formulation aids, can be a variety of dosage forms.

【0024】例えば、本発明のアレルギー性皮膚炎治療用外用薬は、茶葉抽出液、乾燥茶葉および茶葉抽出液の粉体の何れかを、ラノリン、スクワラン、高粘度流動パラフィンおよびワセリン等の低刺激性油性成分等と混合し、さらに適宜添加剤等を加えて、常法により、軟膏およびクリームとすることができる。 [0024] For example, allergic dermatitis therapeutic medicine for external application of the present invention, the tea leaf extract, one of the powder of the dry tea leaves and extract of tea leaves, lanolin, squalane, hypoallergenic, such as high-viscosity liquid paraffin and petrolatum mixed with sexual oily components such as, by adding further appropriate additives such as, by a conventional method, it can be ointments and creams. 本発明の外用薬は、 External medicine of the present invention,
茶葉抽出液と、低刺激性油性成分とを混合し、さらに適宜助剤等を加えて、常法によって、エマルジョンとすることもできる。 And extract of tea leaves, mixing the hypoallergenic oil components in addition further appropriate auxiliaries, etc. in a conventional manner by, may be an emulsion. また、本発明には、茶葉抽出液をそのまま使用し、あるいはさらに生理学上および製剤上許容される助剤、賦香剤、着色料および保存料等を加えて調製された塗布溶液であってもよく、この塗布溶液はスプレー剤として用いることもできる。 Further, the present invention is a tea leaf extract used as is, or further physiologically and formulations acceptable auxiliaries, Fukozai, even coating solution prepared by adding coloring and preservatives such as well, the coating solution can also be used as a spray.

【0025】本発明のアレルギー性皮膚炎治療用外用薬は、特に、乾燥茶葉、茶葉抽出液およびその乾燥体そのもの、あるいはこれらに、生理学上および製剤上許容される助剤、賦香剤、着色料、保存料および賦形剤等を加えた溶液、粉末あるいはタブレットであって、入浴時に浴槽に添加する入浴剤とすることもできる。 The allergic dermatitis therapeutic medicine for external application of the present invention, in particular, dry tea leaves, tea leaf extract and its dry matter itself or to,, auxiliaries acceptable physiologically and formulations, Fukozai, coloring fee, solution or the like by adding preservatives and excipients, a powder or a tablet, may be a bath agent to be added to the bath during bathing.

【0026】以上説明した本発明のアレルギー性皮膚炎治療用外用薬は、ステロイド外用薬と併用することで、 The allergic dermatitis therapeutic medicine for external application of the present invention described above, when used together with topical steroid,
ステロイド外用薬の消炎効果およびアレルギー抑制効果が有効に発揮できるようにし、ステロイド外用薬使用量および使用範囲を低減することができる。 Anti-inflammatory effect and allergic effect of inhibiting steroid external agent to allow effectively exhibit, it is possible to reduce the topical steroid usage and use range.

【0027】本発明の外用薬が、ワセリン等の保湿機能を有する油性成分を含む剤型、例えば軟膏、エマルジョンおよびクリームなどである場合には、入浴後等の皮膚に塗布するだけで、皮膚の保湿保護機能の向上が期待できる。 The external medicine of the present invention, Vaseline moisturizing function including dosage forms the oily components having, for example ointments, if a like emulsions and creams are only applied to the skin, such as after bathing, skin improvement of moisturizing protection function can be expected. 本発明の外用薬が、上述の油性成分を含まない剤型、例えば塗布溶液および入浴剤である場合には、ワセリン等の保湿作用を有する油性成分(保湿剤)を併用することが望ましい。 External medicine of the present invention, agent contains no oil components described above type, for example, when a coating solution and bath agent is desirably used in combination oil component (humectant) having a moisturizing effect of Vaseline.

【0028】特に、本発明の外用薬が入浴剤である場合には、茶葉抽出物が患部炎症部分に作用する以外に、乾燥した皮膚への水分補給および皮膚の洗浄が同時に行なわれるため、皮膚の保護バリヤー機能の回復に特に有効である。 [0028] Particularly, in the case ointments of the present invention is a bath agent, because the tea leaf extract is in addition to acting on the affected area of ​​inflammation, dry hydration and cleaning of the skin to the skin are carried out simultaneously, the skin it is particularly effective in the recovery of the protective barrier function of. また、やむを得ずステロイド外用薬と併用しなければならない場合においても、少量のステロイド外用薬で消炎効果および抗アレルギー効果を得ることができる。 Further, even when the must unavoidably used with topical steroid, it is possible to obtain the anti-inflammatory effect and anti-allergic effects with a small amount of topical steroid.

【0029】 [0029]

【発明の効果】本発明に係るアレルギー性皮膚炎治療用外用薬によれば、茶葉抽出物を有効成分として使用しているため、ステロイド外用薬の使用範囲および使用量を可能な限り低減することができ、かつステロイド外用薬を用いた従来の治療ではその症状に改善が見られなかった場合にも有効なアレルギー性皮膚炎治療用の外用薬を提供することができる。 According to allergic dermatitis therapeutic medicine for external application according to the present invention, due to the use of tea leaf extract as an active ingredient, can be reduced as much as possible the use range and amount of topical steroid it can be, and the conventional treatment with topical steroid may provide ointment for effective allergic dermatitis even when not seen improvement in their symptoms.

【0030】本発明に係る外用薬は、ヒトのアレルギー性皮膚炎の治療、特にアトピー性皮膚炎の治療に好適に使用できる他、ヒト以外の動物、特に犬、猫等の愛玩用哺乳類のアレルギー性皮膚炎の治療にも、ヒトの場合と同様の方法にて、使用することが可能である。 The external medicine of the present invention, the treatment of human allergic dermatitis, other usable particularly advantageously for the treatment of atopic dermatitis, non-human animals, especially dogs, the companion mammals, such as cats allergy in the treatment of sexual dermatitis, in the same manner as in the case of humans, it can be used.

【0031】以下、実施例により、本発明に係るアレルギー性皮膚炎治療用外用薬の効果を更に具体的に説明する。 The following examples further illustrate the effects of allergic dermatitis therapeutic medicine for external application according to the present invention.

【0032】 [0032]

【実施例1】茶の下葉を洗浄・乾燥した後に粉砕し、得られた乾燥茶葉粉末20gを1リットルの熱湯(95 EXAMPLE 1 was ground after washing and drying under tea leaves, resulting dry tea leaves powder 20 g 1 liter hot water (95
℃)で30分間煮出した後、室温に冷却し、次いでろ過することにより、茶葉抽出液750mlを得た。 After boiled for 30 minutes at ° C.), then cooled to room temperature, by filtration then gave the tea leaves extract 750 ml. 得られた茶葉抽出液50mlに0.5gのL-アスコルビン酸ナトリウムを添加し溶解させて1回分の茶葉入浴剤とした。 To the resulting tea leaves extract 50ml was batch of tea leaves bath agent was added and dissolved with L- sodium ascorbate 0.5 g.

【0033】この茶葉入浴液を、乳幼児期にアトピー性皮膚炎と診断され、抗アレルギー剤(商品名:ザジデン)を服用し、かつステロイド外用薬(商品名:リンデロンVG、リンデロンAおよびロコイド軟膏)を併用してきた患者(14歳:男子)の入浴治療に適用した。 [0033] The tea leaves bath liquid, a diagnosis of atopic dermatitis in infancy, antiallergic agent (trade name: Zajiden) taking, and topical steroid (trade name: Rinderon VG, Rinderon A and Rokoido ointments) patients who have a combination of: was applied to the bathing treatment of (14-year-old boys). 治療開始時の患者の症状を表1に示す。 The symptoms of the patient at the time of the start of treatment is shown in Table 1. また、治療は、以下の通りに行なった。 In addition, the treatment was carried out as follows.

【0034】茶葉入浴剤を約200リットルの湯(40 The tea leaves bathing agent about 200 liters of hot water (40
℃)が入れられた浴槽内に添加して入浴治療用湯とした。 ℃) was the bathing treatment for hot water was added to the put it was in the bathtub. 入浴は毎日行ない、1回ごとに5分間以上湯につかることとした。 Bathing is carried out every day, it was decided to soak in hot water for more than five minutes for each one. 入浴時には従来通り低刺激性のコラージュD乾性肌用石鹸を使用した。 At the time of bathing using conventional hypoallergenic collage D dry skin for soap.

【0035】入浴後には、患部にワセリンまたはアズノールを塗布した。 [0035] After bathing, it was coated with vaseline or Azunoru to the affected area. ステロイド外用薬(商品名:リンデロンAおよびロコイド軟膏)を、症状をみて適宜適用した。 Topical steroid (trade name: Rinderon A and Rokoido ointment), were applied appropriately look at the symptoms. 抗アレルギー剤は服用を継続した。 Antiallergic agent was continued taking the drug.

【0036】7日間治療を続けたところ、表1に示すような治療効果が見られた。 [0036] was continued for 7 days treatment, the therapeutic effects were seen such as that shown in Table 1.

【0037】 [0037]

【表1】 [Table 1]

【0038】表1に示すように、茶葉入浴剤を用いた入浴治療によって、アトピー性皮膚炎の症状が改善された。 As shown in Table 1, the bathing treatment with tea leaves bath salts, improved the symptoms of atopic dermatitis. またこの症状改善にともなってステロイド外用薬の使用範囲が減少した。 The range of use of topical steroid was decreased with this symptom improvement.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl. 6識別記号 FI A61K 9/06 A61K 9/06 G 9/08 9/08 M 9/107 9/107 S ────────────────────────────────────────────────── ─── front page continued (51) Int.Cl. 6 identifications FI A61K 9/06 A61K 9/06 G 9/08 9/08 M 9/107 9/107 S

Claims (7)

    【特許請求の範囲】 [The claims]
  1. 【請求項1】茶葉抽出物を有効成分として用いることを特徴とするアレルギー性皮膚炎治療用外用薬。 1. A allergic dermatitis therapeutic topical agent, which comprises using a tea leaf extract as an active ingredient.
  2. 【請求項2】前記茶葉抽出物が、乾燥茶葉、茶葉抽出液および茶葉抽出液乾燥体から選択される何れかの形態で含まれることを特徴とする請求項1に記載のアレルギー性皮膚炎治療用外用薬。 Wherein said tea extract is dried tea leaves, allergic dermatitis according to claim 1, characterized in that contained either in a form selected from the tea leaf extract liquid and the tea leaf extract dried body treatment use external medicine.
  3. 【請求項3】前記茶葉抽出物が、下葉から抽出されることを特徴とする請求項1または2記載のアレルギー性皮膚炎治療用外用薬。 Wherein the tea leaf extract, allergic dermatitis therapeutic medicine for external application according to claim 1 or 2, wherein the extracted from the lower leaves.
  4. 【請求項4】さらにビタミンCおよびビタミンEの少なくとも何れか一方を含むことを特徴とする請求項1〜3 4. The method of claim 1 to 3 further characterized in that it comprises at least one of vitamin C and vitamin E
    の何れか1項に記載のアレルギー性皮膚炎治療用外用薬。 Allergic dermatitis therapeutic medicine for external application according to any one of.
  5. 【請求項5】前記アレルギー性皮膚炎が、アトピー性皮膚炎であることを特徴とする請求項1〜4の何れか1項に記載のアレルギー性皮膚炎治療用外用薬。 Wherein said allergic dermatitis, allergic dermatitis therapeutic topical agent according to claim 1, characterized in that the atopic dermatitis.
  6. 【請求項6】軟膏、溶液、エマルジョンおよびクリームのいずれかの形態であることを特徴とする請求項1〜5 6. Ointments, solutions, claims 1 to 5, characterized in that in the form of either emulsion and cream
    のいずれか1項に記載のアレルギー性皮膚炎治療用外用薬。 Allergic dermatitis therapeutic medicine for external application according to any one of.
  7. 【請求項7】入浴時に浴槽に添加する入浴剤であることを特徴とする請求項1〜5のいずれか1項に記載のアレルギー性皮膚炎治療用外用薬。 7. allergic dermatitis therapeutic topical agent according to claim 1, characterized in that the bath additive is added to the bath during bathing.
JP2274397A 1997-02-05 1997-02-05 Medicine for external use for treating allergic dermatitis Granted JPH10218784A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2274397A JPH10218784A (en) 1997-02-05 1997-02-05 Medicine for external use for treating allergic dermatitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2274397A JPH10218784A (en) 1997-02-05 1997-02-05 Medicine for external use for treating allergic dermatitis

Publications (1)

Publication Number Publication Date
JPH10218784A true true JPH10218784A (en) 1998-08-18

Family

ID=12091197

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2274397A Granted JPH10218784A (en) 1997-02-05 1997-02-05 Medicine for external use for treating allergic dermatitis

Country Status (1)

Country Link
JP (1) JPH10218784A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074326A1 (en) * 2000-03-31 2001-10-11 Shiseido Company, Ltd. Agents improving skin barrier function
WO2001095865A1 (en) * 2000-06-14 2001-12-20 Pure Green Co., Ltd. Oily cosmetics
US6491943B2 (en) * 2000-06-29 2002-12-10 National Agricultural Research Organization Method for treating an allergic or inflammatory disease
US6641846B2 (en) * 2000-11-08 2003-11-04 Tianjin Yanling Health Food Co. Pharmaceutical composition against type I allergy and the preparation thereof
KR100700912B1 (en) 2005-12-30 2007-03-28 고려대학교 산학협력단 Human cell binding of skin acne bacillus containing the acidic polysaccharide isolated from green tea leaves and atopic Staphylococcus aureus inhibitory activity composition
JP2007126373A (en) * 2005-11-01 2007-05-24 Nakakita Yakuhin Co Ltd External preparation for atopic dermatitis and method for producing the same
JP2008031130A (en) * 2006-08-01 2008-02-14 Kao Corp Liquid bathing agent
JP2011006341A (en) * 2009-06-24 2011-01-13 Bathclin Corp Skin external preparation for atopic dermatitis
KR101142977B1 (en) 2009-10-22 2012-05-08 주식회사 코스메카코리아 Cosmetic Composition Comprising Opuntia Five Element Tea Mixed Extract For Improving Atopic skin And Manufacturing Method Thereof And Cosmetic Material Containing The Same

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074326A1 (en) * 2000-03-31 2001-10-11 Shiseido Company, Ltd. Agents improving skin barrier function
WO2001095865A1 (en) * 2000-06-14 2001-12-20 Pure Green Co., Ltd. Oily cosmetics
US7122212B2 (en) 2000-06-14 2006-10-17 Pure Green Co., Ltd. Process for producing oily cosmetics
US6491943B2 (en) * 2000-06-29 2002-12-10 National Agricultural Research Organization Method for treating an allergic or inflammatory disease
US6638524B2 (en) 2000-06-29 2003-10-28 National Agricultural Research Organization Cosmetics, foods and beverages supplemented with purified strictinin
US6899893B2 (en) 2000-06-29 2005-05-31 National Agriculture Research Organization Method for treating an allergic or inflammatory disease
US6641846B2 (en) * 2000-11-08 2003-11-04 Tianjin Yanling Health Food Co. Pharmaceutical composition against type I allergy and the preparation thereof
JP2007126373A (en) * 2005-11-01 2007-05-24 Nakakita Yakuhin Co Ltd External preparation for atopic dermatitis and method for producing the same
KR100700912B1 (en) 2005-12-30 2007-03-28 고려대학교 산학협력단 Human cell binding of skin acne bacillus containing the acidic polysaccharide isolated from green tea leaves and atopic Staphylococcus aureus inhibitory activity composition
JP2008031130A (en) * 2006-08-01 2008-02-14 Kao Corp Liquid bathing agent
JP2011006341A (en) * 2009-06-24 2011-01-13 Bathclin Corp Skin external preparation for atopic dermatitis
KR101142977B1 (en) 2009-10-22 2012-05-08 주식회사 코스메카코리아 Cosmetic Composition Comprising Opuntia Five Element Tea Mixed Extract For Improving Atopic skin And Manufacturing Method Thereof And Cosmetic Material Containing The Same

Similar Documents

Publication Publication Date Title
US6197305B1 (en) Anti-fungal compositions with prolonged activity
US6060070A (en) Isoflavonoids for treatment and prevention of aging skin and wrinkles
US6027716A (en) Synergistic herbal extracts
US6482442B1 (en) Substance mixture for topical application comprising olive oil and honey
US5032400A (en) Shark liver oil and garlic oil topical analgesic
WO2003084553A1 (en) Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis
US20060083708A1 (en) Composition using mineral salts for cosmetic or therapeutic treatment
JP2003212786A (en) Skin care medicament with bamboo extract component as active ingredient
JPH07300412A (en) Active oxygen remover and composition containing the same
JP2000086510A (en) Histamine release inhibitor
JP2003055241A (en) Skin care preparation for preventing itchiness
JP2000014354A (en) Composition having anti-allergic or anti-inflammatory action
US20020176876A1 (en) Topical therapeutic skin care system
JP2005132793A (en) Bleaching agent or dyspigmentation-improving agent
JPH1036276A (en) Antiallergic agent and antiallergic cosmetic material and food containing the same
JPH09208484A (en) Active oxygen-eliminator and composition containing the same
US20090123564A1 (en) Novel compositions for hair disorders and process of preparation thereof
JPH08245409A (en) Skin preparation for external use and bathing agent
US20050152993A1 (en) Composition for and method of treatment for skin ailments
JP2005015456A (en) Prophylactic and therapeutic agent for eczema/dermatitis group
EP0308210B1 (en) Topical treatment of diseased skin disorders
JP2004256485A (en) Skin care preparation for external use
JP2007269743A (en) Skin care preparation
JP2006514657A (en) Wrinkles, the compositions for the treatment of fine lines and excessive sweating and delivery method
JP2002332238A (en) Antiallergic skin care composition

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20041217

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080520